Product Description
Tiancheng Pharmaceutical Technology/Tianyin Jianhua Pharmaceutical Technology is developing icp-105, an Oral FGFR4 Inhibitor for Patients With Advanced Solid Malignancies. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03642834)
Mechanisms of Action: FGFR4 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innocare Pharma
Company Location: Asia Pacific
Company Founding Year: 2015
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03642834 |
ICP-CL-00201 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2020-12-14 |
12% |
2022-07-07 |
|
CTR20181357 |
CTR20181357 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2021-03-01 |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|